Financial Year 2019 31 March 2020 Dr. Andreas Eckert CEO 1 - PowerPoint PPT Presentation

Financial Year 2019 31 March 2020 Dr. Andreas Eckert CEO 1

Globally Globa lly Pos Positi itione oned Niche Niche Play Player er in I in Iso sotope tope Market Market Industrial Components Medical Devices Pharmaceuticals ( ISOTOPE PRODUCTS ) (RADIATION THERAPY) (RADIOPHARMA) Devices Products Implantats Raw materials/ Services Applicators API Projects/ Trade Devices API Disposal Since 1st January 2020: MEDICAL 43 Mio. EUR 106 Mio. EUR 30 Mio. EUR 59% 17% 24% 2019: approx. 180 Mio. Euro revenues Slides only for illustration – the spoken word shall be binding 2

>800 >800 Employ Employee ees (Head (Headco coun unts ts) ) 18 18 Site Sites s Wo World rldwide wide Results 2019 (Mio. EUR) Revenues 178,6 Net Income 22,0 2% 9% 47% 42% EUROPE AMERICA ASIA MIDDLE EAST & AFRICA 3 Slides only for illustration – the spoken word shall be binding

Reven Rev enue ues Incr Increa ease se 1992 1992-2019 2019 180 180 170 160 145 140 138 140 127 120 117 116 120 111 101 in Mio. EUR 100 80 71 60 54 50 42 36 40 33 31 29 24 20 10 8 6 6 4 2 1 0,13 0 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 incl. discontinued and continued operations 4 Slides only for illustration – the spoken word shall be binding

Rev Reven enue ues Gro Grow by by 6% 6% to to 18 180 0 mm mm EUR EUR 2019 Total Revenues 178,6 Mio. EUR 2018 Total Revenues 168,7 Mio. EUR +6% 120,0 100,0 80,0 In Mio. EUR 60,0 40,0 20,0 - Isotope Products Radiation Therapy Radiopharma 2018 106,8 30,4 31,5 2019 105,9 30,1 42,7 incl. discontinued and continued operations Slides only for illustration – the spoken word shall be binding 5

Isot Isotop ope Pro e Produ duct cts s Rev Reven enue ue Gro Growth wth 201 2019, 9, in in Mio. Mio. EUR EUR Flat 120 110 - 4,4 + 3,5 100 90 80 70 106,8 105,9 60 50 40 30 20 Revenues 2018 Organic Growtth Exchange Rate Effects Revenues 2019 Slides only for illustration – the spoken word shall be binding 6

Rad Radioph iophar arma ma Rev Reven enue ue Gro Growth wth 20 2019 19, , in in Mio. Mio. EUR EUR Growing 45 + 1,2 40 + 9,9 35 30 25 42,7 20 31,5 15 10 5 Revenues 2018 Organic Growtth Exchange Rate Effects Revenues 2019 Slides only for illustration – the spoken word shall be binding 7

Rad Radiation iation The Thera rapy py Rev Reven enue ue Gro Growth wth 201 2019, 9, in in Mio. Mio. EUR EUR Flat - 0,7 + 0,5 30 25 20 30,4 30,1 15 10 5 Revenues 2018 Organic Growtth Exchange Rate Effects Revenues 2019 Slides only for illustration – the spoken word shall be binding 8

Ne Net Inc t Incom ome e – Dist Distrib ribut ution ion an and Gr d Growth wth FY 2019 FY 20 19 Slides only for illustration – the spoken word shall be binding 9

Net Net I Inc ncome ome Gro Grows ws by by 36 36% to 22 % to 22 mm mm EUR EUR 2019 Total Net Income 22,0 Mio. EUR +36% 2018 Total Net Income 16,1 Mio. EUR 14,0 12,0 10,0 In Mio. EUR 8,0 6,0 4,0 2,0 0,0 Isotope Products Radiation Therapy Radiopharma 2018 11,6 0,7 6,4 2019 10,3 1,5 12,0 Slides only for illustration – the spoken word shall be binding 10

Net Net I Inc ncome ome Gro Growth wth all all Seg Segmen ments ts in 201 in 2019, 9, in in Mio. Mio. EUR EUR The action is here 25,0 + 0,7 20,0 + 5,6 - 1,2 + 0,9 15,0 22,0 10,0 16,1 5,0 0,0 Net income 2018 Isotope Products Radiation Therapy Radiopharma Holding Net income 2019 Slides only for illustration – the spoken word shall be binding 11

Isot Isotop ope Pro e Produ duct cts s Net Net Inco Income me Gro Growth wth 201 2019, 9, in in Mio. Mio. EUR EUR Flat 14 - 0,3 + 1,0 - 0,4 12 + 0,1 - 1,2 10 8 6 11,6 10,3 4 2 0 Net income 2018 Industry UWD Gamma Exchange Rate Effects Tax/Interest Net income 2019 Slides only for illustration – the spoken word shall be binding 12

Rad Radioph iophar arma ma Net Net Inco Income me Gro Growth wth 201 2019, 9, in in Mio. Mio. EUR EUR Growing 20 18 + 2,1 16 + 0,0 + 1,0 14 - 2,5 + 11,2 12 10 8 + 12,0 6 4 + 6,4 2 0 Net income 2018 Revenues COGS Sales and Marketing Administrative and Exchange Net income 2019 Costs Development Costs Rate/Interesrt/Tax Slides only for illustration – the spoken word shall be binding 13

Rad Radiation iation The Thera rapy py Net Net Inco Income me Gro Growth wth 201 2019, 9, in in Mio. Mio. EUR EUR Flat 1,6 + 0,1 1,4 1,2 0,5 1,0 0,0 0,1 0,8 1,5 0,6 0,6 0,4 0,7 - 0,5 0,2 0,0 Net income 2018 Revenues COGS Sales and Administrative Exchange Minorities Net income 2019 Marketing Costs and Development Rate/Interesrt/Tax Interest Costs Slides only for illustration – the spoken word shall be binding 14

Cas Cashflo hflow and w and Balan Balance ce She Sheet et FY FY 20 2019 19 Slides only for illustration – the spoken word shall be binding 15

Balan Balance ce She Sheet et as as of of 31 31/12/2 /12/201 019, 9, in in Mio. Mio. EUR EUR Cash 79 Equity 138 Recievables 29 Minority Interests 1 Inventory 31 IFRS 16 Leasing 20 Intangible Assets 71 Accruals/Provisions 67 Fixed Assets 40 Other Short Term Payables 40 Others 23 Other Long Term Payables 7 Total Activ 274 Total Passiv 274 • Cash at Hand 79 Mio. EUR • Debt Free • Equity Ratio 51% Slides only for illustration – the spoken word shall be binding 16

Balan Balance ce She Sheet et Ext Exten ension sion ex exclus clusively ively du due to e to IFRS IFRS Changes in Non-Current Assets, in mm EUR: No increase in balance sheet risks despite growth in 2019 Slides only for illustration – the spoken word shall be binding 17

Ne Net L t Liqu iquidity idity in Mio. EUR, year end +10 mm EUR Share Buy-Back 80 80 70 70 60 60 50 50 In Mio. EUR 40 40 30 30 20 20 10 10 0 0 2014 2015 2016 2017 2018 2019 Liquidity 22 31 37 58 54 79 Loan 19 16 12 2 0 0 Net Liquidity 3 15 25 56 54 79 Folie nur zur Illustration – es gilt das gesprochene Wort 18

Cas Cashflow i hflow in n 20 2019 19 in Mio. in Mio. EUR EUR EBITDA: 44,2 Mio. EUR 100,0 -5,6 90,0 -10,0 0,5 Growth 80,0 39,9 70,0 60,0 50,0 78,9 40,0 30,0 54,2 20,0 10,0 0,0 Liquidity 31.12.18 CF Operating Activities CF Investing Activities CF Financing Activities Exchange Rate Effects Liquidity 31.12.19 Slides only for illustration – the spoken word shall be binding 19

Pr Profita ofitability bility (Net (Net Inc Incom ome/ EP e/ EPS) S) Basis: 5,2 Mio. shares 4,3 4,5 23,0 4,0 21,0 3,1 3,5 19,0 3,0 17,0 22,0 2,2 2,5 15,0 2,0 1,9 2,0 13,0 16,1 14,7 1,3 Industry& RI 1,5 11,0 10,7 1,0 9,0 10,2 0,5 7,0 6,8 5,0 0,0 2014 2015 2016 2017 2018 2019 im Mio EUR/Aktie Slides only for illustration – the spoken word shall be binding 20

Stock Sto ck and and Dividen Dividend, d, in E in EUR/St UR/Stoc ock 200 1,70 180 160 1,50 140 1,30 120 1,7 100 1,10 80 0,90 60 1,2 40 0,70 0,8 20 0,66 0,60 0,60 0,60 0,50 0 2014 2015 2016 2017 2018 2019 2020 Dividend in EUR/Share EUR/Aktie Slides only for illustration – the spoken word shall be binding 21

Impro Improve ved Pro Profi fita tabili bility ty Since Since 20 2014 14 Turn Turnar arou ound nd • 2014 – Acquisition of Brazilian Isotope Specialist REM – Accreditation Gallium Generator/ API – New Management Board in Therapy Segment • 2015 – Sale of US-Seed Business to Theragenics – Closing of Oxford/ (US) – Profitable Sales of OPS to IPSEN • 2016 – Acquisition of Belgian Brachytherapie Unit – Acquisition of Brazilian Transports Specialist – FDA-Approval for NETSPOT/ (API of EZAG) • 2017 – Sale of Cyclotron Business to Alliance Medical – Acquisition of Gamma-Service Group, Leipzig • 2018  Acquisition of WOMED  Merger BEBIG S.A. und EZAG AG • 2019 until today  First Chinese bridgeheads established  Lutetium Production started  Profitable Sale of Production Site in Seneffe, Belgium  Attractive Development Pipeline 22 Slides only for illustration – the spoken word shall be binding

Firs First Mil t Miles esto tone nes s Ach Achieve ieved in C in China hina Eckert & Ziegler has formed a joint venture with TCL Health Care for the distribution of tumor irradiation devices in China Slides only for illustration – the spoken word shall be binding 23